Valeant Pharmaceuticals International, Inc. · Mississauga, ON Canada (Toronto: VRX)
Key Valeant Pharmaceuticals International, Inc. Financials
| Company Type | Public -(Toronto: VRX) Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Sales (mil.) | $2,463.5 |
| 2011 Employees | 6,900 |
Valeant Pharmaceuticals International, Inc. Income Statement
| Dec 11 | Dec 10 | Dec 09 | |
| Revenue | 2,463.5 | 1,181.2 | 820.4 |
| Cost of Goods Sold | 726.8 | 405.8 | 204.3 |
| Gross Profit | 1,736.6 | 775.5 | 616.1 |
| Gross Profit Margin | 70.5% | 65.7% | 75.1% |
| SG&A Expense | 584.3 | 367.4 | 190.4 |
| Depreciation & Amortization | 557.8 | 219.8 | 104.7 |
| Operating Income | 300.0 | (110.1) | 181.2 |
| Operating Margin | 12.2% | -9.3% | 22.1% |
| Nonoperating Income | 11.0 | (43.2) | 18.1 |
| Nonoperating Expenses | (329.0) | (83.0) | (24.3) |
| Income Before Taxes | (18.0) | (236.3) | 175.0 |
| Income Taxes | (177.6) | (28.1) | (1.5) |
| Net Income After Taxes | 159.6 | (208.2) | 176.5 |
| Continuing Operations | 159.6 | (208.2) | 176.5 |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 159.6 | (208.2) | 176.5 |
| Total Net Income | 159.6 | (208.2) | 176.5 |
| Net Profit Margin | 6.5% | -17.6% | 21.5% |
| Diluted EPS from Total Net Income | 0.49 | (1.06) | 1.11 |
| Dividends per Share | 0.0 | 0.28 | 0.65 |
All amounts in millions of US Dollars except per share amounts.
Valeant Pharmaceuticals International, Inc. Balance Sheet
| Assets | Dec 11 | Dec 10 | Dec 09 |
| Current Assets | |||
| Cash | 164.1 | 394.3 | 114.5 |
| Net Receivables | 577.5 | 283.1 | 119.9 |
| Inventories | 355.2 | 229.6 | 82.8 |
| Other Current Assets | 260.7 | 113.3 | 33.5 |
| Total Current Assets | 1,357.5 | 1,020.2 | 350.6 |
| Net Fixed Assets | 414.2 | 281.8 | 103.8 |
| Other Noncurrent Assets | 11,370.0 | 9,493.2 | 1,612.6 |
| Total Assets | 13,141.7 | 10,795.1 | 2,067.0 |
| Liabilities | Dec 11 | Dec 10 | Dec 09 |
| Current Liabilities | |||
| Accounts Payable | 157.6 | 101.3 | 72.0 |
| Short-Term Debt | 111.3 | 116.9 | 12.1 |
| Other Current Liabilities | 655.4 | 474.2 | 172.8 |
| Total Current Liabilities | 924.3 | 692.5 | 256.9 |
| Long-Term Debt | 6,539.8 | 3,574.5 | 380.2 |
| Other Noncurrent Liabilities | 1,670.7 | 1,617.1 | 75.6 |
| Total Liabilities | 9,134.7 | 5,884.0 | 712.7 |
| Shareholder's Equity | |||
| Preferred Stock Equity | -- | -- | -- |
| Common Stock Equity | 4,007.0 | 4,911.1 | 1,354.4 |
| Total Equity | 4,007.0 | 4,911.1 | 1,354.4 |
| Shares Outstanding (thou.) | 306,371.0 | 302,448.9 | 158,310.9 |
All amounts in millions of US Dollars except per share amounts.
Valeant Pharmaceuticals International, Inc. Cash Flow Statement
| Dec 11 | Dec 10 | Dec 09 | |
| Net Operating Cash Flow | 676 | 263 | 361 |
| Net Investing Cash Flow | (2,844.5) | 228.9 | (742.8) |
| Net Financing Cash Flow | 1,948.2 | (213.3) | 177.0 |
| Net Change in Cash | (230.2) | 279.8 | (203.1) |
| Depreciation & Amortization | 557.8 | 219.8 | 104.7 |
| Capital Expenditures | (386.0) | (16.8) | (569.3) |
| Cash Dividends Paid | 0.0 | (356.3) | (147.1) |
All amounts in millions of US Dollars except per share amounts.